Document Detail


Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium.
MedLine Citation:
PMID:  16198398     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To define the efficacy of thalidomide on the overall survival of patients with metastatic recurrent gynecologic sarcomas. PATIENTS AND METHODS: All patients with sarcoma or carcinosarcoma of gynecologic origin and documented recurrence or persistence of disease after appropriate surgery, radiation therapy and/or chemotherapy were recruited to the study. All patients were ambulatory and had measurable disease that could be documented on CT scan. Patients were started on 200 mg/day of thalidomide orally every night and escalated by 100-200 mg every 7 to 14 days. The length of the treatment was separated into 2 cycles with the first 84 days defined as the first cycle and the next 56 days as the second cycle. Common Toxicity Criteria were used to record toxicities. Because thalidomide was postulated to induce cytostasis, the end-points were progression-free and overall survival in this mixed group of patients. RESULTS: Seventeen patients were enrolled. The drug was not well tolerated because of constipation, fatigue, worsening performance status, drowsiness and sleepiness. The total dosage of medication given to each patient ranged from 3200 mg to 40,500 mg. The maximum dosage reached in each patient ranged from 300 mg to 750 mg, with the total time of treatment ranging from 13 to 99 days. All patients had progression of disease with a median progression-free survival time of 1.84 months (CI 1.54-2.79 months) and a median overall survival of 6.64 months. DISCUSSION: Thalidomide has no activity in patients with advanced or recurrent gynecologic sarcomas and was not well-tolerated. The overall survival was <7 months. The progression-free survival was <3 months, and, since the therapy was not tolerated well, we unanimously decided to close the study at this point. Despite the poor result, we still believe in the strategy of anti-angiogenesis and will continue to pursue other potential treatment options using the same concept.
Authors:
D Yi-Shin Kuo; Patrick Timmins; Stephanie V Blank; Abbie L Fields; Gary L Goldberg; Anthony Murgo; Paul Christos; Scott Wadler; Carolyn D Runowicz
Related Documents :
22609618 - Field match verification during combination proton, photon, and electron therapy for ol...
20166208 - Grading of nonrhabdomyosarcoma soft tissue sarcoma in children and adolescents: a compa...
22849978 - Neoadjuvant chemotherapy as ovarian cancer treatment: ever more used with major regiona...
22643538 - Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer pat...
10554638 - Preliminary results of simultaneous radiochemotherapy with paclitaxel for urinary bladd...
17094408 - The association of immunoreactive p53 and ki-67 with t-stage, grade, occurrence of meta...
Publication Detail:
Type:  Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2005-09-29
Journal Detail:
Title:  Gynecologic oncology     Volume:  100     ISSN:  0090-8258     ISO Abbreviation:  Gynecol. Oncol.     Publication Date:  2006 Jan 
Date Detail:
Created Date:  2005-12-21     Completed Date:  2006-02-09     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0365304     Medline TA:  Gynecol Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  160-5     Citation Subset:  IM    
Affiliation:
Division of Gynecologic Oncology, Department of Obstetrics/Gynecology, Weill Medical College of Cornell University, New York, NY 10021, USA. dek2001@med.cornell.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Carcinosarcoma / drug therapy*
Female
Genital Neoplasms, Female / drug therapy*
Humans
Neoplasm Recurrence, Local / drug therapy
Sarcoma / drug therapy*
Thalidomide / adverse effects,  therapeutic use*
Treatment Outcome
Grant Support
ID/Acronym/Agency:
N01-CM-17103-74/CM/NCI NIH HHS
Chemical
Reg. No./Substance:
50-35-1/Thalidomide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibri...
Next Document:  Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous ca...